Categories: HealthcareNews

MediWound to Participate in the 2024 Maxim Healthcare Virtual Summit

YAVNE, Israel, Oct. 08, 2024 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced that Chief Executive Officer Ofer Gonen will take part in a fireside chat during the 2024 Maxim Healthcare Virtual Summit. The fireside chat, hosted by Michael Okunewitch, Senior Biotechnology Analyst at Maxim, will take place on Wednesday, October 16, 2024, at 9:30 a.m. ET.

To attend the virtual fireside chat, please register here. In addition, the MediWound management team will be available for one-on-one meetings throughout the summit. Interested investors are encouraged to contact their Maxim representative to schedule a meeting.

About MediWound

MediWound Ltd. (Nasdaq: MDWD) is a global leader in next-generation enzymatic therapeutics focused on non-surgical tissue repair. The Company specializes in the development, production and commercialization of rapid and effective biologics that enhance existing standards of care and improve patient experiences while reducing healthcare costs and unnecessary surgeries.

MediWound’s first drug, NexoBrid®, is FDA and EMA-approved as an orphan biologic for eschar removal in deep partial-thickness and/or full-thickness thermal burns, significantly reducing the need for surgical interventions. Building on its proprietary enzymatic platform, MediWound is advancing EscharEx®, a promising candidate currently in Phase III development for the debridement of chronic wounds. With distinct advantages over the current $360+ million market leader, EscharEx offers a unique opportunity for significant market expansion.

For more information visit www.mediwound.com and follow us on LinkedIn.

   
MediWound Contacts:  
Hani Luxenburg Daniel Ferry
Chief Financial Officer Managing Director
MediWound Ltd. LifeSci Advisors, LLC
ir@mediwound.com  daniel@lifesciadvisors.com 
   
Media Contact:  
Ellie Hanson  
FINN Partners for MediWound  
ellie.hanson@finnpartners.com   
+1-929-588-2008  
   

Staff

Recent Posts

Apollo Neuroscience Announces 2025 Year in Review

Community Gains Nearly 144 Million Minutes of Sleep, Wins Best Sleep Wearable of 2025NEW YORK,…

6 hours ago

Paytient Recognized by Modern Healthcare for Transforming Patient Experience

COLUMBIA, Mo., Jan. 30, 2026 /PRNewswire/ -- Paytient, a leader in innovative healthcare affordability and…

6 hours ago

Promino Announces Closing of Private Placement

Burlington, Ontario--(Newsfile Corp. - January 30, 2026) - Promino Nutritional Sciences Inc. (CSE: MUSL) (OTC:…

10 hours ago

NuGen Medical Devices Inc. Announces CFO Transition

Toronto, Ontario--(Newsfile Corp. - January 30, 2026) - NuGen Medical Devices Inc. (TSXV: NGMD) ("NuGen"…

12 hours ago

Midmark RTLS launches BLE Sensory Network for smarter, scalable RTLS

New Plug-In BLE Sensors provide a faster, more cost-effective path to facility-wide RTLS coverage with near-room…

12 hours ago

Vrtly, Inc. Unveils End-to-End In-Practice Marketing Platform, Bridging the “Blind Spot” for Brands in Cash-Pay Healthcare

DANVILLE, Calif., Jan. 30, 2026 /PRNewswire/ -- Vrtly, Inc., the premier point-of-care (POC) marketing platform…

12 hours ago